Sanofi reports first Phase III data for new insulin glargine formulation

Sanofi (Euronext:SAN; NYSE:SNY) reported data from a pair of open-label Phase III trials evaluating once-daily subcutaneous U300 in over 1,600 Type II diabetics. In the EDITION I trial, U300 as an add-on to mealtime insulin led to the same reduction in mean HbA1c from baseline to six months, the primary endpoint, vs. the pharma's Lantus insulin glargine once daily as an add-on to mealtime insulin (0.83% for both). In Edition II, U300 as an add-on to oral antidiabetic drugs led to a similar reduction in HbA1c from baseline to six months vs. Lantus as an add-on to oral antidiabetic drugs. Data were presented at the American Diabetes Association meeting in Chicago. ...